A delivery system plus transdermal platform that combines biomechanical activation with programmable molecular instruction, bringing Vector’s cGMP-manufactured Rx peptides, made using pharma-grade Active Pharmaceutical Ingredients (APIs), through the skin to the tissue where they need to act.
The athlete and performance biomechanical product platform being developed by Vector Science & Therapeutics, built to bring Vector’s transdermal peptide platform to elite athletes and the sports medicine professionals who care for them.
The platform delivers peptide-based molecular instruction transdermally, aiming for site-directed signaling at the tissue level: tendons, ligaments, fascia and nearby blood vessels. It draws on Vector’s portfolio of cGMP-manufactured Rx peptides, made using pharma-grade APIs, with a verified chain of control from production to the physician.
The delivery system prepares the tissue and drives transport, drawing on Vector’s biomechanical and electrically assisted delivery technologies.
cGMP-manufactured Rx peptides move through the skin without injection, including a wearable platform that uses a pulsed magnetic field (provisional patent, June 2026).
Programmable molecular instruction is designed to target, complement and support repair and resilience in tendons, ligaments and fascia.
The platform is in development. Vector’s peptides are Rx-labeled products for physician use only. Descriptions reflect Vector’s press releases of June 12 and July 8, 2026 and are forward-looking.
See the transdermal and deep-tissue delivery patents behind this platform, or contact our team.